VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | The current standard of care in advanced stage HL

Jonathan W Friedberg, MD, MMSc, University of Rochester, Rochester, NY, discusses the current standard of care in advanced stage Hodgkin lymphoma (HL), emphasizing the various regimens used in Europe versus the United States. Following this, Dr Friedberg goes on to discuss how response-adapted treatment has been widely researched in HL, and the benefits and drawbacks of this approach. To conclude, Dr Friedberg discusses the ECHELON-1 trial, which demonstrated a progression-free survival (PFS) and overall survival (OS) benefit in patients in the brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) arm, and how this regimen has become the standard of care in many countries. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter